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Abstract
There is an ongoing debate on the therapeutic potential of vaso-modulatory interventions against glioma
invasion. Prominent vasculature-targeting therapies involve functional tumour-associated blood vessel
deterioration and normalisation. The former aims at tumour infarction and nutrient deprivation medi-
ated by vascular targeting agents that induce occlusion/collapse of tumour blood vessels. In contrast,
the therapeutic intention of normalising the abnormal structure and function of tumour vascular net-
works, e.g. via alleviating stress-induced vaso-occlusion, is to improve chemo-, immuno- and radiation
therapy efficacy. Although both strategies have shown therapeutic potential, it remains unclear why they
often fail to control glioma invasion into the surrounding healthy brain tissue. To shed light on this
issue, we propose a mathematical model of glioma invasion focusing on the interplay between the mi-
gration/proliferation dichotomy (Go-or-Grow) of glioma cells and modulations of the functional tumour
vasculature. Vaso-modulatory interventions are modelled by varying the degree of vaso-occlusion. We
discovered the existence of a critical cell proliferation/diffusion ratio that separates glioma invasion re-
sponses to vaso-modulatory interventions into two distinct regimes. While for tumours, belonging to one
regime, vascular modulations reduce the tumour front speed and increase the infiltration width, for those
in the other regime the invasion speed increases and infiltration width decreases. We show how these in
silico findings can be used to guide individualised approaches of vaso-modulatory treatment strategies
and thereby improve success rates.
Keywords: glioma invasion; go-or-grow mechanism; vaso-modulatory interventions; vascular occlusion
and normalization; invasion speed and infiltration width; mathematical modelling.
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2Introduction
Malignant gliomas are aggressive brain tumours typically associated with a poor prognosis, sharp dete-
rioration in the patients’ quality of life and markedly low survival rates, making this disease a challenge
to treat. According to the World Health Organization (WHO) [1], gliomas are classified into different
categories varying from low-grade (slow-growing) to high-grade (rapidly-growing) tumours depending on
their proliferative capacity and invasiveness, glioblastoma multiforme (GBM) being the most malignant
form. Despite advances in surgical and medical neuro-oncology [2, 3], complete tumour resection is un-
likely and subsequent recurrence is almost inevitable. A major obstacle to cure this devastating type
of brain tumours is attributed to its highly invasive nature. Glioma cells have a remarkable capacity to
infiltrate the surrounding normal brain tissue and migrate long distances from the tumour bed, which
enables them to escape surgical resection, radiation exposure and chemotherapy [4–6]. The persistently
poor prognosis and high treatment failure rates demand more effective therapeutic strategies that should
be based on a deeper mechanistic understanding of the key events triggering tumour invasion.
The influence of the microenvironment on the behaviour of glioma cells plays a crucial role in the
resulting diffusive tumour growth and infiltration into the adjacent brain tissue. Hypoxia, the pres-
ence of abnormal and sustained low oxygen levels in the tumour tissue, strongly correlates with glioma
malignancy [7]. At higher glioma cell densities, tumours contain hypoxic regions with an inadequate
oxygen supply due to tumour-induced vascular abnormalities. Under such oxygen-limiting conditions,
glioma cells develop a wide variety of rescue mechanisms to survive and sustain proliferation. These
include recruitment of new blood vessels driven by secretion of pro-angiogenic factors, modulations of cell
oxygen consumption and activation of cellular migratory mechanisms to escape from poorly oxygenated
regions [8–11]. In particular, the ability of glioma cells to switch phenotype in response to metabolic stress
may have important implications for tumour progression and resistance to therapies. For instance, the
mutually exclusive switching between proliferative and migratory phenotypes experimentally observed,
and known as the migration/proliferation dichotomy (or Go-or-Grow mechanism), is considered to signif-
icantly increase invasiveness in response to low oxygen levels [4, 10,12–14]. However, how the dynamical
interplay between glioma cells and their microenvironment leads to development of hypoxic regions, as
well as their global impact on glioma invasion are still not fully understood.
A particularly important component of the tumour microenvironment is the vasculature. There exist
various positive and negative feedback mechanisms between glioma cells and the vasculature. Gliomas are
reported as highly vascularised neoplasias [15, 16], where excessive vascularisation is induced by a wide
range of pro-angiogenic factors [17, 18]. However, over-expression of pro-angiogenic factors produced by
hypoxic glioma cells is commonly observed and results in local vascular hyperplasia with defective blood
vessels. Such morphological abnormalities in the vasculature are a common feature of gliomas, where
blood vessels have significantly larger diameters and thicker basement membranes than those in normal
brain tissue [15], see Figure 1(A,B). Moreover, vaso-occlusive events have been reported to initiate a
hypoxia/necrosis cycle influencing the dynamical balance between migration and proliferation of glioma
cells. In fact, different pathological and experimental observations suggest that vaso-occlusion could
readily explain the rapid peripheral expansion and diffusely infiltrative growth behaviour of malignant
gliomas [19,20]. Blood vessel occlusion can mainly occur due to increased mechanical pressure exerted on
them by tumour cells or induced by intravascular pro-thrombotic mechanisms [21,22], see Figure 1(C,D).
Occluded or collapsed blood vessels induce perivascular tumour hypoxia and favour glioma cell migration
towards better oxygenated regions. This fact has been linked to waves of hypoxic glioma cells actively
migrating away from oxygen-deficient regions leading to pseudopalisade formation [19–21, 23]. Since
hypoxia-induced migration is recognised to support further neoplastic dissemination, investigating the
overall effect of vaso-modulatory interventions on the tumour front speed and infiltration width turns
crucial.
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Figure 1: Histological images of functional and occluded blood vessels in malignant gliomas.
(A) From right to left brain tissue infiltrated by glioma cells with meningeal blood vessels of normal size
and anatomy. (B) Atypical and not occluded intratumoural blood vessels with activated endothelium
and thicker/plumper muscular layers than the normal brain vessels. (C) A longitudinal section of a
large intratumoural blood vessel with a not obliterated part filled with blood (left) and an occluded part
(right). (D) Thrombotic occlusion in small intratumoural blood vessels. The arrowheads point to blood
vessels which are magnified in the corresponding subfigures.
The high degree of angiogenesis and vascular pathologies observed in malignant gliomas have been
the target of several vaso-modulatory strategies [24, 25]. Current clinical and preclinical findings sug-
gest that angiogenesis inhibitors alone, with the potential to starve glioma cells, have limited efficacy in
terms of tumour shrinkage, functional vasculature destruction and patient survival [26–28]. Furthermore,
anti-angiogenic factors as inhibitors of neovascularisation are also restricted by transient effects and de-
velopment of therapy resistance [29]. Instead, improved tumour vascularisation, either via normalisation
or due to a stress alleviation strategy based on reopening compressed blood vessels, is an emerging con-
cept expected to reduce tumour hypoxia, improve perfusion and enhance the delivery of cytotoxic drugs
and radiotherapy efficacy [24, 30–32]. Recent evidences indicate that judicious application of an anti-
angiogenic therapy may normalise the structure and function of tumour vasculature [28, 30, 31], where
potential benefits are schedule- and patient-dependent [33,34]. Although vasculature-targeting interven-
4tions could provide therapeutic benefits, further mechanistic insights into glioma invasion responses are
still needed to improve treatment outcomes and patient survival [24,32].
In this work, we propose a mathematical model of reaction-diffusion type that is based on well-
supported biological assumptions for the growth of vascularised gliomas. In particular, we focus on the
interplay between the migration/proliferation dichotomy of glioma cells and modulations of functional
tumour vasculature. Mathematical modelling has the potential to improve our understanding of the com-
plex biology of tumours and their interactions with the microenvironment, as well as may help to design
more effective and personalised therapeutic strategies [35–43]. Several mathematical models have been
developed to identify mechanisms that facilitate proliferation and migration of glioma cells [16,38,44–53],
see also [54, 55] for reviews. Most of these models have been formulated to study glioma invasion based
exclusively on cell diffusion and proliferation rates [44–47,49]. Among modelling results, interpretation of
glioma growth patterns compared to clinical data [47, 49], as well as plausible predictions of the success
or failure of different treatment techniques have been reported [44, 45, 48, 50, 52, 56]. Recently, different
models including the influence of tumour microenvironmental conditions such as hypoxia, necrosis and
angiogenesis have been developed [16, 38, 53]. However, the role of vaso-occlusion in glioma invasion,
considering the Go-or-Grow mechanism, has not been addressed so far. Accordingly, we intend to gen-
erate insights into the effects of vaso-modulatory interventions on tumour front speed and infiltration
width. The main aim is to use the better understanding to investigate the potential of personalised
therapeutic protocols. To that end, we begin by defining the biological assumptions taken into account
when developing our glioma-vasculature interplay model. We then investigate the effect of modulations
of cell oxygen consumption and vaso-occlusion rates in glioma invasion. We show that one-size-fits-all
vaso-modulatory interventions should be expected to fail to control glioma growth and lead to a trade-off
between tumour front speed and infiltration width. The model results provide a better understanding
of glioma-microenvironment interactions, and it is therefore suited for analysing the potential success or
failure of vaso-modulatory treatment strategies. We conclude with a discussion of the main implications
of our model results in designing novel personalised therapeutic protocols.
Materials and Methods
A glioma-vasculature interplay model
The mathematical model we develop describes the growth of vascularised gliomas focusing on the inter-
play between the migration/proliferation dichotomy and vaso-occlusion at the margin of viable tumour
tissue. The system variables are density of glioma cells ρ(x, t) and functional tumour vasculature v(x, t),
as well as concentrations of oxygen σ(x, t) and pro-angiogenic factors a(x, t) in the tumour microenviron-
ment, where (x, t) ∈ Rd × R and d is the dimension of the system. Figure 2(A) shows a diagram of the
system interactions/assumptions considered, which are summarised as follows:
[A1] Glioma cells switch phenotypes between proliferative (normoxic) and migratory (hypoxic) depending
on the oxygen concentration in the tumour microenvironment [4, 10,12–14].
[A2] Under hypoxia conditions glioma cells secrete large amounts of pro-angiogenic factors [15,17,18,24].
[A3] Pro-angiogenic factors drive new blood vessel formation and vasculature remodelling [18,28].
[A4] Endothelial cells uptake pro-angiogenic factors [18,57].
[A5] Functional tumour-associated vasculature releases oxygen [15,17,18].
[A6] Oxygen availability is essential for glioma growth and progression [17,18,58].
[A7] Glioma cells consume oxygen provided by the existing functional vascular network [17,59].
[A8] Prothrombotic factors and high mechanical pressure induce vaso-occlusion in gliomas [19,23,58,60].
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A role for VEGF in abnormal DC differentiation was 
first demonstrated in vitro93 and addition of neutral-
izing VEGF antibodies resulted in normal maturation 
of DCs93. These initial in vitro findings were confirmed 
in vivo. Administration of recombinant VEGF to tumour-
free mice resulted in defective DC development and an 
accumulation of Gr-1+ (also know as LY6G+) immature 
myeloid-derived suppressor cells101. Furthermore, pre-
treatment of mice with VEGF inhibited FLT3 ligand 
stimulation of DC differentiation from bone marrow pro-
genitor cells102. Treatment of tumour-bearing mice with 
neutralizing VEGF antibodies resulted in an increased 
number of spleen and lymph node DCs and improved DC 
differentiation101,102. Treatment with VEGF-targeted anti-
bodies was also shown to improve anti-tumour peptide 
cytotoxic T-lymphocyte responses and efficacy of tumour 
immunotherapy in mouse models102. Thus, VEGF is a 
strong negative modulator of DC function in the tumour 
microenvironment, which contributes to immune 
privilege of tumours in the host. The potential pathways 
through which VEGF can inhibit DC differentiation 
have been investigated (BOX 1).
These preclinical findings suggest that blockade of 
VEGF signalling could improve anti-tumour responses 
in patients through improvement in DC function and 
immune recognition of tumour cells. Although intrigu-
ing, this hypothesis has been studied only to a limited 
extent clinically.
In a phase I study of VEGF trap, DC and immune 
function was tested in 15 patients103,101. VEGF trap did 
not affect the total population of DCs, their myeloid 
or plasmacytoid subsets, myeloid-derived suppressor 
cells or regulatory T cells. VEGF trap did appear to 
significantly increase the fraction of mature DCs, 
suggesting that DC differentiation was improved in 
these patients. However, VEGF trap treatment was not 
associated with an overall increase in non-specific or 
antigen-specific T-cell responses. As these results were 
generated in a small patient cohort, it is difficult to 
draw conclusions from these data. Clearly, additional 
studies in larger patient populations are warranted to 
fully understand the importance of VEGF-targeted 
therapy on immune function in cancer patients. It will 
also be important to study VEGF-targeted therapy in 
combination with other tumour immunotherapy 
strategies, such as anti-CTLA4 and tumour vaccine 
therapies, that directly aim to enhance the immune 
response against tumours.
Counteracting VEGF and/or EPC upregulation
One mechanism by which VEGF-targeted therapy 
may be of benefit to patients is by counteracting the 
upregulation of VEGF expression following genotoxic 
stress induced by chemotherapy or radiation therapy. 
VEGF expression is upregulated by variations in the 
microenvironment that are associated with stress, such 
as hypoxia, low pH and nutrient deprivation. Genotoxic 
stress induced by chemotherapy and radiation therapy 
has also been found to induce VEGF expression.
Human melanoma cells treated with dacarbazine 
led to an increase in secreted VEGFA and interleukin 8 
(IL8)102. In these studies, the authors found an induction 
of VEGF levels and increased promoter activity. In a 
follow-up study, this group showed that dacarbazine-
resistant melanoma cell lines demonstrated increased 
growth in vivo with increased microvessel density103. 
Others have shown that ultraviolet irradiation or pho-
todynamic therapy can increase tumour cell VEGF 
secretion from keratinocytes or prostate cancer cells, 
respectively104. Lastly, irradiated tumour cells were 
shown to have increased expression levels of VEGF. 
Importantly, sublethal irradiation actually led to an 
induction of in vivo tumour growth hypothesized to 
be secondary to increased VEGF secretion102. Our 
laboratory has recently shown that oxaliplatin induces 
VEGFA and other members of the VEGF family of 
ligands including PlGF and VEGFC. We also studied 
the effect of acute exposure (6–24 h) of oxaliplatin in 
induction of VEGF receptors on tumour cells, and 
found that VEGFR1 is induced by oxaliplatin exposure. 
Thus, one proposed mechanism of action of VEGF- 
targeted therapy is to offset induction of VEGF signalling, 
presumed to be survival signals for tumour cells.
Figure 6 | Tumour-derived vascular endothelial growth factor (VEGF) inhibits 
maturation of dendritic cells (DCs). VEGF and other tumour-derived factors recruit 
immature DCs (iDCs) from the bone marrow and peripheral tissues to sites of tumour 
growth. Apoptotic tumour cells in the tumour microenvironment release tumour antigens 
that are engulfed by iDCs, resulting in their activation and differentiation into mature 
dendritic cells (mDCs). These mDCs migrate to peripheral lymph nodes where they 
present tumour antigens in the context of major histocompatibility complex (MHC) 
class I and II antigens to CD4+ and CD8+ T cells. VEGF released by tumour cells inhibits 
the maturation of of iDCs to mDCs, resulting in inefficient presentation of tumour 
antigens and immune privilege of tumour cells. VEGF-targeted therapy has the 
potential to reverse the negative effects of VEGF on iDC maturation, resulting in more 
efficient presentation of tumour antigens to the host immune system. GM–CSF, 
granulocyte macrophage colony-stimulating factor; HPC, haematopoietic progenitor 
cell; IL3, interleukin 3; TCR, T-cell receptor; VEGFR, VEGF receptor.
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These preclinical findings suggest that blockade of 
VEGF signalling could improve anti-tumour responses 
in patients through improvement in DC function and 
immune recognition of tumour cells. Although intrigu-
ing, this hypothesis has been studied only to a limited 
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not affect the total population of DCs, their myeloid 
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Figure 2: Modelling logic and hierarchy. (A) Diagram of the interacti ns between glioma cells,
oxygen, functional tumour-associated vasculature and pro-angiogenic factors. (B) From left to right
model complexity increases with respect to the interactions between system variables: density of glioma
cells ρ, density of functional tumour vasculature v and oxygen c c ration σ. σ0 and v0 r presen a
constant oxygen concentration and functional tumour vascularisation. The model parameters g2 and h2
are the rates of vaso-occlusion and glioma cell oxygen consumption, respectively (see equations (11)-(12)).
6Density of glioma cells
Based on the migration/proliferation dichotomy [4,10,12–14], we assume that glioma cells ρ(x, t) switch
between two different cell phenotypes, migratory ρ1(x, t) (hypoxic) and proliferative ρ2(x, t) (normoxic),
depending on the concentration of oxygen in the tumour microenvironment described by σ(x, t). More
precisely, we consider two linear switching functions, f21(σ) = λ1 − σ and f12(σ) = λ2σ, that represent
the rate at which glioma cells change from migratory to proliferative and vice versa, respectively. The
parameters λ1 and λ2 are positive constants, see the Supplementary Material for further details. Cell
motility is modelled as a diffusive process mimicking the net invasion of glioma cells into the surrounding
brain tissue, while a logistic growth term is considered for tumour cell proliferation. Accordingly, the
system of equations governing the dynamics of migratory and proliferative glioma cells is given by
∂ρ1
∂t
= Dρ∇2ρ1 − f12(σ)ρ1 + f21(σ)ρ2, (1)
∂ρ2
∂t
= bρ ρ2 (1− (ρ1 + ρ2)/N) + f12(σ)ρ1 − f21(σ)ρ2, (2)
where the temporal t and spatial x coordinates in the arguments of variables have been omitted for
notational simplicity. Dρ and bρ are the diffusion and proliferation rates of migratory and proliferative
glioma cells, respectively. N represents the brain tissue carrying capacity, i.e. the maximum number of
cells that can be located within a domain element. The model parameters Dρ, bρ and N are positive
constants.
The system (1)-(2) is reduced to a single equation for the total density of glioma cells ρ = ρ1 + ρ2
by assuming that f12(σ)ρ1 = f21(σ)ρ2. This assumption implies that each phenotypic switching event
is faster compared to migration and proliferation cell processes, which allows to express ρ1 and ρ2 as a
function of ρ in the following form
ρ =
(
1 +
f12(σ)
f21(σ)
)
ρ1 =
(
1 +
f21(σ)
f12(σ)
)
ρ2,
where we have that
ρ1 =
(
1
1 + f12(σ)/f21(σ)
)
ρ
and
ρ2 =
(
1
1 + f21(σ)/f12(σ)
)
ρ.
Summing equations (1) and (2), and substituting the expressions above for ρ1 and ρ2, we obtain the
governing equation for the total (migratory and proliferative) density of glioma cells as follows
∂ρ
∂t
= Dρ∇2(α(σ)ρ) + bρ β(σ)ρ (1− (α(σ) + β(σ))ρ/N) , (3)
where the oxygen-dependent functions α(σ) and β(σ) are given by
α(σ) =
1
1 + f12(σ)/f21(σ)
=
λ1 − σ
(λ2 − 1)σ + λ1 , (4)
and
β(σ) =
1
1 + f21(σ)/f12(σ)
=
λ2σ
(λ2 − 1)σ + λ1 . (5)
7Then, taking into account that α(σ) + β(σ) = 1, we can rewrite equation (3) as
∂ρ
∂t
= Dρ∇2(α(σ)ρ) + bρ β(σ)ρ (1− ρ/N) . (6)
We notice that equation (6) is a generalisation of the widely studied Fisher-Kolmogorov model to
describe glioma invasion [55,61]. The nonlinear terms α(σ) and β(σ) in equation (6) modify the rates of
cell diffusion and proliferation according to oxygen availability. Under hypoxic conditions cell diffusion
increases, while proliferation decreases, i.e. glioma cells become more migratory and less proliferative. On
the contrary, for normal oxygen levels glioma cells become more proliferative and less invasive. Let σ0 > 0
be the physiological concentration of oxygen in the host brain tissue. Then, by normalising Dρ = D/α(σ0)
and bρ = b/β(σ0) the classical Fisher-Kolmogorov equation is recovered under the assumption of a
constant oxygen concentration
∂ρ
∂t
= D∇2ρ+ b ρ (1− ρ/N) , (7)
where D and b are positive constants denoting respectively the intrinsic rates of diffusion and proliferation
of glioma cells. Equation (7) has been extensively used to predict untreated glioma invasion kinetics,
as well as to estimate patient-specific parameters based on standard medical imaging [16, 49, 55, 62].
Furthermore, this model allowed for suitable estimations of glioma recurrence after surgical resection [50]
and simulations of tumour responses to conventional therapeutic modalities as chemo- [48] and radiation
therapy [56].
Pro-angiogenic factor concentration
Neovascularisation in tumours takes place when pro-angiogenic factors overcome anti-angiogenic stimuli.
However, in gliomas there is a wide range of pro- and anti-angiogenic factors involved, each of them acting
through different vascularisation mechanisms [15, 24, 28]. While not explicitly considering the vascular
endothelial growth factor (VEGF) or any other pro-angiogenic molecule, we assume a generic effective
pro-angiogenic factor concentration a at quasi-steady state. In fact, we suppose that an over-expression of
pro-angiogenic factors instantaneously promotes formation of functional tumour vasculature. We further
assume that pro-angiogenic factors are only produced by glioma cells under hypoxic conditions at a rate
proportional to tumour cell density, and therefore neglect hypoxia-independent pathways. Moreover,
pro-angiogenic factors are consumed by endothelial cells and undergo natural decay. The equation for
the effective pro-angiogenic factor concentration a(x, t) is given by
0 = k1 ρ H˜θ(σ − σ∗a)− k2av − k3a,
where
a =
k1 ρ H˜θ(σ − σ∗a)
k2v + k3
. (8)
The positive constants k1, k2 and k3 represent the production, consumption and natural decay rates,
respectively, where 0 < σ∗a < σ0 is the hypoxic oxygen threshold for production of pro-angiogenic factors
by glioma cells. The function H˜θ(σ− σ∗a) is a continuous approximation of the Heaviside decreasing step
function H(ξ), which is defined as H(ξ) = 1 if ξ ≤ 0 and H(ξ) = 0 if ξ > 0, and given by
H˜θ(σ − σ∗a) = 1−
1
1 + e−2θ(σ−σ∗a)
, (9)
where θ is a positive constant that controls the steepness of H˜θ at (σ − σ∗a).
8Density of functional tumour vasculature
Several experimental findings support that vascular structure and function become markedly abnormal
in brain tumours [17,18,58]. Malignant gliomas, and particularly glioblastomas, have blood vessels of in-
creased diameter, high permeability, thickened basement membranes and highly proliferative endothelial
cells [15], see also Figure 1(B). Due to such abnormalities, a significant fraction of the tumour-associated
vascular network does not constitute functional blood vessels [15]. Based on these observations, we exclu-
sively account for functional vascularisation instead of modelling the total density of tumour blood vessels.
Accordingly, we assume that the density of functional tumour vasculature v(x, t) is a dimensionless and
normalised quantity with values in the interval [0, 1]. The normal density of functional vascularisation in
the host brain tissue is taken equal to v = 1/2. The limit case v = 0 represents an avascular tissue, while
on the contrary v = 1 describes a hypothetical scenario characterised by excessive vascularisation.
Blood vessels in gliomas are not stable, being continuously formed, occluded and destroyed. Neovas-
cularisation takes place by different angiogenic and vasculogenic processes induced by complex signalling
mechanisms that are not well understood [11, 63, 64]. For simplicity, we assume that tumour blood ves-
sels are created when pro-angiogenic factors prevail anti-angiogenic stimuli, i.e. for a > 0, leading to
development of new functional vasculature according to a logistic growth term. The rate at which such
vasculature is generated follows the Michaelis-Menten kinetics depending on the pro-angiogenic factor
concentration, where diffusive vascular dispersal at a constant rate is assumed. On the other hand,
mechanical or chemical cues in regions of high glioma cell density induce blood vessel occlusion or col-
lapse [19, 23, 60]. Vaso-occlusion is then modelled by an exponential term depending on the density of
glioma cells. The equation for the density of functional tumour vasculature v(x, t) is given by
∂v
∂t
= Dv∇2v + g1 a
µ+ a
v (1− v)− g2vρn, (10)
where the temporal t and spatial x coordinates in the arguments of variables have been omitted for
notational simplicity. Dv is the diffusion coefficient representing the net dispersal of functional tumour
vasculature, g1 is the maximum formation rate of functional blood vessels, µ is the pro-angiogenic factor
concentration at which g1 is half-maximal, g2 is the vaso-occlusion rate and n is a parameter that controls
the degree of vaso-occlusion depending on the density of glioma cells. The model parameters Dv, g1, µ,
g2 and n are positive constants.
Plugging equation (8) for effective pro-angiogenic factor concentration into equation (10), and as-
suming that the decay rate of a is much smaller than the consumption rate by endothelial cells, i.e.
k3  k2 [65], we obtain that
∂v
∂t
= Dv∇2v + g1
ρ
v
H˜θ(σ − σ∗a)
K +
ρ
v
H˜θ(σ − σ∗a)
v (1− v)− g2vρn, (11)
where K = µk2/k1 is a positive constant denoting the concentration of pro-angiogenic factors at which
the functional tumour vasculature formation rate is half-maximal, see the Supplementary Material for
more details.
Oxygen concentration
Oxygen is delivered to the host brain tissue via functional blood vessels, spreads into the tumour mass and
is consumed by glioma cells. Transport of oxygen within tissues occurs by diffusion and convection [66].
For simplicity, we neglect the convective contributions and only consider that after transvascular exchange
oxygen molecules move exclusively by diffusion. Oxygen supply is modelled by assuming that the supply
rate is proportional to the functional vascularisation and the difference between the physiological oxygen
9concentration in the host brain tissue and that in the tumour interstitium. These assumptions result in
the following equation for the oxygen concentration σ(x, t)
∂σ
∂t
= Dσ∇2σ + h1v (σ0 − σ)− h2ρσ, (12)
where the temporal t and spatial x coordinates in the arguments of variables have been omitted for
notational simplicity. Dσ is the oxygen diffusion coefficient, h1 is the permeability coefficient of functional
blood vessels, σ0 is the physiological oxygen concentration in the host brain tissue and h2 is the oxygen
consumption rate by glioma cells. The model parameters Dσ, h1, σ0 and h2 are positive constants.
Similar assumptions have been previously considered to model oxygen-related mechanisms in tumour
growth [22].
Model formulation, boundary and initial conditions
The proposed model of glioma-vasculature interplay comprises the following system of coupled partial
differential equations
∂ρ
∂t
= Dρ∇2(α(σ)ρ) + bρ β(σ)ρ (1− ρ/N) , (13)
∂v
∂t
= Dv∇2v + g1
ρ
v
H˜θ(σ − σ∗a)
K +
ρ
v
H˜θ(σ − σ∗a)
v (1− v)− g2vρn, (14)
∂σ
∂t
= Dσ∇2σ + h1v (σ0 − σ)− h2ρσ, (15)
where the oxygen-dependent functions α(σ) and β(σ) are given by equations (4)-(5), respectively. The
system of equations above is closed by imposing the following initial conditions
ρ(x, 0) = ρ0H˜γ(x− ) = ρ0
(
1− 1
1 + e−2γ(x−)
)
, 0 ≤ x ≤ L,
v(x, 0) = v0, 0 ≤ x ≤ L,
σ(x, 0) = σ0, 0 ≤ x ≤ L,
where the positive constants ρ0, σ0 and v0 are the initial density of glioma cells located in a small segment
of length , density of functional tumour vasculature and oxygen concentration, respectively. The length
of the one-dimensional simulation domain is represented by L > 0, and γ is a positive constant that
controls the steepness of H˜γ at (x− ) with  > 0. Moreover, we consider an isolated host tissue in which
all behaviours arise due to the interaction terms. This assumption results in no-flux boundary conditions
of the form
ρx(0, t) = vx(0, t) = σx(0, t) = 0, 0 ≤ t ≤ Tf ,
ρx(L, t) = vx(L, t) = σx(L, t) = 0, 0 ≤ t ≤ Tf ,
where Tf > 0 is an arbitrary time. These boundary conditions also imply that no cell or molecule leaves
the system through the tissue/domain boundaries.
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Modelling hierarchy
The glioma-vasculature interplay model given by equations (13)-(15), and referred to as model III, is a
generalisation of two simpler models which are also of interest for the study of glioma invasion. As shown
in Figure 2(B), such simpler models are obtained under the assumptions of constant density of functional
tumour vasculature v(x, t) = v0 (model II), and also constant oxygen concentration σ(x, t) = σ0 (model I).
Specifically, model II is obtained from model III by setting g1 = g2 = 0 in equation (14), i.e. assuming
neither formation nor occlusion/collapse of tumour blood vessels. In turn, model I is obtained from
model II by setting h2 = 0 in equation (15), i.e. assuming a constant concentration of oxygen in the
tumour microenvironment.
Model I is similar to the classical Fisher-Kolmogorov equation (7), for which a large number of theo-
retical and simulation results are known [55, 61]. Model II given by equations (13) and (15) contains an
extended version of the Fisher-Kolmogorov equation with nonlinear glioma cell diffusion and proliferation
terms. Both nonlinearities depend on the oxygen concentration in the tumour microenvironment, which
is governed by a reaction-diffusion equation with linear diffusion and nonlinear reaction terms. In addi-
tion, the dynamics of the glioma cell population are modelled by considering the migration/proliferation
dichotomy (Go-or-Grow). As in model II the supply of oxygen is assumed constant, the blood perfusion
is stable and we neglect tumour-induced vascular pathologies. The latter is a a reasonable assumption,
especially for low grade gliomas, where abnormal vasculature is not prominent [16]. A natural extension of
model II is to consider tumour-associated vascularisation dynamics. Accordingly, model III is formulated
to investigate the effects of vaso-modulatory interventions on glioma invasion. Taking into account the
huge amount of results reported from model I, we analyse model II as an intermediate step towards the
study of model III, see Figure 2(B). In particular, we focus on the impact of glioma cell oxygen consump-
tion and vaso-occlusion modulations on tumour front speed and infiltration width. In the Supplementary
Material we provide details about model simulations and the numerical implementation.
Model observables
We characterise glioma invasion by the tumour front speed and infiltration width, see Figure S1 in the
Supplementary Material. The tumour front speed is estimated by the rate of change given by the point
of maximum slope in ρ(x, t) at the end of numerical simulations Tf . In turn, the infiltration width is
defined by the difference between the points where glioma cell density is 80% and 2% of the maximum
cell density at time Tf . These tumour invasion properties have been reported crucial to determine glioma
malignancy and therapeutic failure rates [16,50,55].
Unlike the mathematical model given by the classical Fisher-Kolmogorov equation (7), in our glioma
invasion model given by equations (13)-(15) cell processes are regulated by oxygen availability. Thus, we
distinguish intrinsic cell diffusion D and proliferation b rates from effective rates which take into account
the oxygen concentration in the tumour microenvironment. Accordingly, the effective diffusion Deff and
proliferation beff rates are defined as
Deff = Dρ L
−1
∫
L
α(σ(x, t)) dx (16)
and
beff = bρ L
−1
∫
L
β(σ(x, t)) dx, (17)
where L represents the length of the one-dimensional domain of simulation, Dρ = D/α(σ0) and bρ =
b/β(σ0), where D and b are the intrinsic rates of glioma cell diffusion and proliferation, respectively. The
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parameter σ0 is the physiological concentration of oxygen in the host brain tissue. In the following, we
investigate the dependence of Deff and beff at time Tf , as well as the tumour front speed and infiltration
width, for different ranges of model parameters h2 (cell oxygen consumption) and g2 (vaso-occlusion).
Model parameterisation
Model parameter values are taken from published data wherever possible or estimated to approximate
physiologic conditions based on appropriate physical arguments, see Table 1 and the Supplementary
Material for further details. For parameters of special interest, a wide range of values is considered to
explore their effects on the resulting glioma invasion.
Table 1: Model parameter values (see the Supplementary Material).
Parameter Description Value Source
Glioma Cells
D Intrinsic diffusion rate of glioma cells [2.73× 10−3, 2.73× 10−1] mm2 day−1 [16, 55,67]
b Intrinsic proliferation rate of glioma cells [2.73× 10−4, 2.73× 10−2] day−1 [16, 55,67]
N Brain tissue carrying capacity 102 cells mm−1 [68, 69]
σ0 Physiological oxygen concentration 1.0 nmol mm−1 [70, 71]
λ1 Phenotypic switching parameter (†) 2.0 nmol mm−1 Model specific
λ2 Phenotypic switching parameter (‡) {0.5, 1.0, 2.0} Model specific
Oxygen
Dσ Diffusion rate of oxygen 1.51× 102 mm2 day−1 [22, 72,73]
h1 Oxygen supply rate 3.37× 10−1 day−1 [74–76]
h2 Oxygen consumption rate [5.73× 10−3, 1.14× 10−1] mm cell−1 day−1 [77, 78]
Vasculature
Dv Vasculature dispersal rate 5.0× 10−4 mm2 day−1 [16, 22,79]
g1 Vasculature formation rate 10−1 day−1 [22, 80,81]
σ∗a Oxygen concentration threshold for hypoxia 2.5× 10−1 nmol mm−1 [73, 82,83]
K Half-maximal pro-angiogenic factor concentration 1.0 nmol mm−1 Estimated
g2 Vaso-occlusion rate [5.0× 10−13, 1.5× 10−11] cell−n mmn day−1 Estimated
n Dimensionless vaso-occlusion degree 6 Estimated
(†) Proliferative to migratory. (‡) Migratory to proliferative.
Results
Increasing cell oxygen consumption and vaso-occlusion result in more diffusive
and less proliferative gliomas
The glioma-vasculature interplay model given by equations (13)-(15) is first used to investigate the effects
of cell oxygen consumption and vaso-occlusion modulations on the effective behaviour of gliomas. Fig-
ures 3(A,B) and 4(A,B) provide simulation maps of effective diffusion Deff and proliferation beff rates,
as defined in equations (16) and (17), for gliomas characterised by different combinations of intrinsic cell
coefficients D and b. Model simulations in Figure 3(A,B) are obtained under the assumption of constant
functional vasculature density, i.e. neither formation nor occlusion/collapse of tumour blood vessels,
for increasing oxygen consumption rates by glioma cells. In turn, Figure 4(A,B) provides simulation
maps for a fixed oxygen consumption rate considering tumour vascularisation dynamics and increasing
vaso-occlusion rates.
Comparative simulation maps in Figures 3(A,B) and 4(A,B) illustrate that increasing the rate of
oxygen consumption by glioma cells h2 and vaso-occlusion g2 result in more diffusive and less proliferative
tumours. Modulations of the oxygen consumption rate have major impact on highly infiltrative and
rapidly growing gliomas. At high values of both parameters, h2 and g2, the oxygen concentration in the
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tumour microenvironment significantly decreases. The lack of oxygen limits the proliferative capacity of
glioma cells, and in turn enhances the hypoxia-induced cell migration towards better oxygenated brain
tissue regions. The precise way in which such changes in glioma cell dynamics affect invasion responses
are predicted to depend on the intrinsic tumour features.
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Figure 3: Oxygen consumption effects on glioma invasion for constant functional tumour
vasculature. Simulation maps with respect to the intrinsic proliferation b ∈ [2.73 × 10−4, 2.73 ×
10−2] days−1 and diffusion D ∈ [2.73 × 10−3, 2.73 × 10−1] mm2 days−1 rates of glioma cells. (A)
Effective diffusion, (B) effective proliferation, (C) tumour front speed and (D) infiltration width for
different oxygen consumption rates h2 = {5.73 × 10−4, 5.73 × 10−3, 5.73 × 10−2} mm cell−1 day−1 in
simulation maps I-III respectively. (A-D) Differences between simulation maps are provided. The other
model parameters are as in Table 1.
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Figure 4: Vaso-occlusion effects on glioma invasion. Simulation maps with respect to the intrinsic
proliferation b ∈ [2.73×10−4, 2.73×10−2] days−1 and diffusion D ∈ [2.73×10−3, 2.73×10−1] mm2 days−1
rates of glioma cells. (A) Effective diffusion, (B) effective proliferation, (C) tumour front speed and (D)
infiltration width for a fixed oxygen consumption h2 = 5.73× 10−3 mm cell−1 day−1 and different vaso-
occlusion g2 = {5.0× 10−13, 5.0× 10−12, 1.5× 10−11} cells−n mmn day−1 rates in simulation maps I-III
respectively. (A-D) Differences between simulation maps are provided. The other model parameters are
as in Table 1.
Modulations of cell oxygen consumption and vaso-occlusion rate result in op-
posing effects on glioma invasion
Figures 3(C,D) and 4(C,D) show simulation maps of tumour front speed and infiltration width with re-
spect to different combinations of intrinsic cell coefficients D and b. In particular, these glioma invasion
properties are determined by a non-linear relationship between effective diffusion Deff and proliferation
beff of glioma cells. For instance, in the simplest case of model I similar to the classical Fisher-Kolmogorov
equation (7), the tumour front speed is proportional to
√
Deff beff and infiltration width
√
Deff/beff.
Model simulations predict that, depending on the intrinsic tumour features, modulations of cell oxygen
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consumption and vaso-occlusion rates produce opposing effects on the resulting front speed and infil-
tration width. These findings are counter-intuitive and might have important implications for possible
modulatory interventions targeting cell oxygen consumption and vaso-occlusion in gliomas, as discussed
below.
Cell oxygen consumption variations reveal a critical proliferation rate for
glioma invasion
Model analysis, under the assumption of constant density of functional tumour vasculature, reveals that
modulations of the rate h2 at which glioma cells consume oxygen produce opposing effects on the tumour
front speed. More precisely, Figure 3(C) reveals that there exists a critical proliferation rate b∗ for which
the front speed of gliomas characterised by b > b∗ decreases at higher values of h2, while on the contrary
tumours with b < b∗ invade faster. Assuming that tumour front speed is proportional to the product
of effective diffusion and proliferation rates, we can easily understand the afore-mentioned results for
variations of h2. In particular, above the critical proliferation rate b
∗ effective diffusion and proliferation
negate each other and leave the resulting front speed almost invariant. For b < b∗, the effective tumour
proliferation remains intact, but the effective diffusion capacity increases for raising h2 values inducing
higher front speeds.
The flatness/steepness of tumour fronts is determined by a relation dependent on the ratio of effective
diffusion and proliferation rates. When oxygen is not limited, highly diffusive tumours evolve with large
and flat fronts, whereas increased cell proliferation results in short and steep fronts. However, under
oxygen-limiting conditions this relation is markedly influenced by the specific rate at which glioma cells
consume oxygen. Figure 3(D) shows that variations in the cell oxygen consumption rate have always
the same overall impact on the tumour infiltration width. Comparative simulation maps reveal that
whatever the intrinsic tumour features, an arbitrary increase (decrease) in the cell oxygen consumption
rate produces larger (smaller) infiltrative responses. Indeed, the effective glioma proliferation capacity
is reduced for increasing oxygen consumption rates and in turn hypoxia-induced effective migration is
enhanced, yielding more infiltrative tumour growth patterns.
Modulation of tumour vaso-occlusion reveals a critical cell proliferation/diffusion
ratio for glioma invasion
Model simulations show that for rising vaso-occlusion rates g2, the front speed is affected differently
depending on the intrinsic diffusion and proliferation rates of glioma cells. In this case, glioma invasion
is additionally influenced by vascularisation mechanisms. Comparative simulation maps in Figure 4(C)
suggest that tumours with features inside a region delimited by a critical proliferation rate b+ and an
approximate ratio between cell diffusion and proliferation rates Λ+ = b/D invade faster as g2 increases.
The tumour front speed out of such region decreases or remains invariant. Gliomas characterised by
b < b+ evolve at low cell density and thus vaso-occlusive events hardly occur. On the other hand,
increasing vaso-occlusion rates for b > b+ enhances effective migration towards better vascularised brain
tissue areas. Although vaso-occlusion limits the proliferative activity of glioma cells, faster front speeds
are obtained as long as the induced migratory responses dominate.
The infiltration width of gliomas with b < b+ is almost unaffected for increasing vaso-occlusion
rates as shown in Figure 4(D). However, gliomas characterised by b > b+ are also separated by an
approximated linear relationship between cell coefficients D and b with respect to variations in the
infiltration width. In particular, increasing vaso-occlusive events results in larger flat fronts for gliomas
with cell proliferation/diffusion ratios above the critical one, while the infiltration width decreases in the
remaining cases.
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Discussion
In this work, we developed a deterministic mathematical model of glioma invasion which is formulated as
a system of reaction-diffusion equations. The model accounts for the dynamics of normoxic and hypoxic
glioma cells based on the Go-or-Grow mechanism and influenced by the functional tumour-associated vas-
culature, as well as concentrations of pro-angiogenic factors and oxygen in the tumour microenvironment.
Specifically, we focused on the effects of cell oxygen consumption and vascular modulations on relevant
properties of glioma invasion, i.e. tumour front speed and infiltration width. The main simulation results
of the model are summarised in Figure 5.
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Figure 5: Overview of model simulation results. (A) Modulations of cell oxygen consumption
under the assumption of constant functional vasculature density reveal a critical proliferation rate b∗ in
glioma invasion responses (model II). (B) Modulations of functional tumour-associated vasculature reveal
a critical proliferation/diffusion ratio Λ+ = b/D for proliferation rates higher than b+ in glioma invasion
responses (model III). Colour gradients from low to high represent the increase of cell oxygen consumption
and vaso-occlusion rates. The purple and black wedges/bars represent the resulting effects on tumour
front speed and infiltration width, for increasing/decreasing cell oxygen consumption and vaso-occlusion
rates.
The model analysis reveals that increasing cell oxygen consumption and vaso-occlusion rates result in
more diffusive and less proliferative gliomas. In both scenarios, the average oxygen concentration in the tu-
mour microenvironment decreases which limits cell proliferation and enhances hypoxia-induced migration.
However, the extent to which such oxygen-mediated cell responses to vasculature-targeting treatment in-
terventions influence glioma invasion depends on the specific intrinsic tumour features. Modulations of
the functional tumour-associated vasculature reveals the existence of a critical cell proliferation/diffusion
ratio for glioma invasion responses, see Figure 5(B). This fact is observed for gliomas evolving with suf-
ficiently high cell proliferation rates for variations in the oxygen concentration, due to vaso-occlusion or
normalisation, significantly influences tumour cell dynamics. In such cases, tumour vascular modulations
are predicted to produce opposing effects on front speed and infiltration width. Moreover, we found
that depending on the intrinsic tumour features two distinct regimes can be identified where invasive
16
behaviours in responses to vaso-modulatory interventions are different. A pro-thrombotic treatment is
predicted to increase front speeds, but in turn reduces infiltration capacity of gliomas characterised by a
cell proliferation/diffusion ratio below the critical threshold. On the contrary, gliomas in the other regime
under the same treatment strategy become increasingly infiltrative and slowly growing. Analogously, vas-
cular normalisation therapies produce opposing results for the corresponding parameter regimes.
Recently, it has been shown that the migration/proliferation dichotomy introduces a critical glioma cell
density threshold separating tumour growth and extinction dynamics, a phenomenon called Allee effect
[14]. Here, we also identify critical parameter values that distinguish different glioma invasive behaviours
with respect to variations of cell oxygen consumption or vaso-occlusion. Interestingly, this is an emergent
consequence of the Go-or-Grow plasticity, since in its absence (see model I ) no critical behaviour is
observed. Assuming or not tumour vasculature dynamics, the Go-or-Grow induced criticality is expressed
either in the form of a critical intrinsic proliferation/diffusion ratio Λ+ or an intrinsic proliferation rate
b∗, respectively, see Figure 5. This result highlights the importance of further investigating the clinical
effects of the Go-or-Grow phenomenon on glioma invasion.
The above in silico findings demonstrate that one-size-fits-all vaso-modulatory interventions should
be expected to fail to control glioma invasion due to the complexity of the involved mechanisms and
the heterogeneity of patient- and tumour-related factors. This study proves the value of personalised
treatment strategies based on a precise tumour profiling and provides a modelling framework with the
potential to parametrise model predictions based on biopsy measurements. In particular, individual es-
timation of intrinsic proliferation and diffusion rates, for instance via biopsy tumour sample analysis,
would be crucial components of such future tailored approaches to personalised glioma therapy. More-
over, this work substantially expands the current theoretical concepts in glioma invasion, showing that
any vasculature-targeting therapeutic intervention will inevitably lead to a trade-off between tumour front
speed and infiltration width. This finding suggests that vaso-modulatory therapies should be embedded in
personalised combination therapy regimens, in which anti-angiogenesis might be integrated with individ-
ually adjusted other modules targeting proliferation, metabolism or tumour immunology. For instance,
in the case of gliomas characterised by a high intrinsic proliferation/diffusion ratio, a pro-thrombotic or
an anti-vasogenic treatment technique may reduce tumour invasion speed, but at the same time leads to
highly infiltrative responses that makes this therapeutic strategy rather inappropriate. However, select-
ing a blood vessel normalisation strategy results in faster growing gliomas as a bulk with less-infiltrating
morphologies. Thus, surgical resection could be considered to remove such compact tumours. In turn,
the benefits of conventional treatments such as chemotherapy, radiotherapy and immunotherapy might
increase in better-vascularised tumours [24, 30–32]. Therefore, an accurate glioma patient stratification
during clinical decision-making is predicted relevant for the efficacy of vasculature-targeting therapies,
based on either tumour-associated blood vessel deterioration or normalisation.
This work provides a mathematical framework for exploring novel approaches to rational combination
therapies or regimens composed of subsequent periods of vaso-modulatory interventions and potentially
other therapeutic modules. In our model the vaso-occlusion term is rather phenomenological and more
accurate modelling is required. Furthermore, the migration/proliferation dichotomy has been modelled
in the simplest possible way and more informed models could be integrated. In turn, intra-tumour ge-
netic diversity is not directly considered, but we take into account phenotypic diversity depending on the
oxygen availability, that is crucial for therapeutic outcomes. The latter is supported by evidences that
genetic diversity is tumour-subtype specific and not significantly affected during treatment, while phe-
notypic heterogeneity is different before and after therapy [84]. Despite the fact that the model involves
a large number of model parameters, their values were defined independently from each other based on
published experimental data. For those parameters estimated, a parametric analysis was performed and
we concluded that variations of their values do not affect the general conclusions of this study. At this
stage, we restrict the modelling strategy to the effects of vasculature-targeting therapies, however, we
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are aware of the fact that further aspects of tumour biology may play a crucial role. In fact, we aim
to investigate the interactions between the immune system and angiogenesis as an additional level of
complexity given the potential success of immunomodulatory therapies. In particular, macrophages are
likely to be involved in relevant mechanisms and will be included in future developments of the current
approach. This is particularly relevant in the light of recent advanced in molecular classification of malig-
nant gliomas [85]. Mathematical modelling provides an integrative approach for conventional radiological,
biopsy and molecular tumour characterization, allowing for the prediction of glioma treatment responses
and translation into clinical decision-making.
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Supplementary Material
1.1 Numerical implementation
Numerical solutions of the proposed glioma-vasculature interplay model are obtained by implementing
the finite element method and backward Euler scheme for spatial and temporal discretisation, respectively
[86, 87]. The system of coupled partial differential equations (17)-(19) is first transformed into a weak
formulation, which results in a system of ordinary differential equations with respect to time. The one-
dimensional domain of simulation over which such equations are numerically solved is divided into a
finite number of distinct and non-overlapping linear elements. The integrals involved in the weak form
of the system are calculated on each domain element by means of a Gaussian quadrature formula, which
exactly integrates the resulting polynomials [88]. The backward Euler scheme is then used to obtain
a temporal discretisation that results in a nonlinear system of equations solved at each instant of time
by the Newton-Raphson method [86]. Model simulations were carried out using MATLAB software
(www.mathworks.com) in a SuSE Linux Enterprise Server 11 with 5888 core AMD Opteron 6274 2.2GHz,
92 nodes each with 64 cores and 64 to 512 GB of memory.
1.2 Simulation domain
The system of equations (17)-(19) is solved in a one-dimensional domain Ω of length L = 200 mm for a
total simulation time of 3 years, i.e. Tf = 1095 days. The independent system variables are time t and
space x with 0 ≤ x ≤ L and 0 ≤ t ≤ Tf . The x-axis can be thought of as a two-dimensional domain
which is spatially averaged in one direction. The simulation domain, either inside the region occupied
by glioma cells or outside representing the host brain tissue, is discretised into an irregular grid varying
from a minimum segment length of 2.5×10−3 mm to a maximum one of 2.5×10−2 mm. The time step is
taken equal to 0.25 day, i.e. 6 hours. Both, segment length and time step are properly selected to ensure
numerical stability.
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1.3 Model observables
We characterise glioma invasion by the tumour front speed and infiltration width. The front speed is
estimated by the rate of change given by the point of maximum slope in ρ(x, t) at the end of numerical
simulations Tf , see Figure S1. In turn, the infiltration width is defined by the difference between the
points where glioma cell density is 80% and 2% of the maximum cell density ρ at time Tf .
Glioma Cells
Carrying Capacity (N)
Tumour 
Front
Infiltration Width
mm
0.80 ρ
0.02ρ
ρ
ρ
Figure 6: Model observables. The tumour front is defined by the point of maximum slope in ρ(x, t)
(green) and infiltration width (red).
2 Model parameterisation
2.1 Initial conditions
Density of functional tumour vasculature and oxygen concentration are initialised in the domain Ω as
v0 = 1/2 and σ0 = 1.0 nmol mm
−1, respectively. In turn, the initial number of glioma cells, p0 =
40 cells mm−1, is modulated by the continuous approximation of the Heaviside decreasing step function
H˜γ(x−) = 1−
(
1/
(
1 + e−2γ(x−)
))
for x ∈ Ω, with γ = 1.0×101 and  = 0.5. The latter choice provides
continuity on the model initial conditions and guarantees numerical stability. At both extremes of the
simulation domain Ω, no-flux boundary conditions are imposed.
2.2 Density of glioma cells, ρ(x, t)
- Intrinsic diffusion rate of glioma cells D (in mm2 day−1). Several studies using a data-driven
Fisher-Kolmogorov model support that the diffusion rate of glioma cells is a patient-specific parameter
[16,52,55,56,89]. Estimates of D vary from 2.73× 10−3 to 2.73× 10−1 mm2 day−1, which is supposed to
cover low to high grade gliomas [16, 52, 55, 67]. Notice that Dρ = D/α(σ0), see equation (4) where α(σ)
is defined.
- Intrinsic proliferation rate of glioma cells b (in day−1). Similar as reported for the diffusion
rate of glioma cells, b is also suggested to be patient-specific [16, 52, 55, 56, 89]. Estimates of b vary from
2.73 × 10−4 to 2.73 × 10−2 day−1, which is supposed to cover low to high grade gliomas [16, 52, 55, 67].
Notice that bρ = b/β(σ0), see equation (5) where β(σ) is defined.
- Brain tissue carrying capacity N (in cells mm−1). This model parameter describes the limiting
concentration of glioma cells that a volume of host brain tissue can hold. Considering an average glioma
cell diameter of about 10 µm [16], the one-dimensional carrying capacity is about 102 cells mm−1. This
estimate is in line with previous values considered for modelling of glioma growth [68,69].
- Physiological oxygen concentration in the host brain tissue σ0 (in nmol mm
−1). Although in
vivo estimates of oxygen pressure in the brain tissue may vary with respect to measurement methods and
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other factors, a suitable experimental value for σ0 is 40 mmHg [70,71,90,91]. Henry’s law [92] is used to
obtain the concentration of oxygen in the brain tissue as follows
σ0 = 40/kH ≈ 2.068 nmol mm−3,
where kH = 1.93420922505× 1010 mm3 mmHg mol−1 is the Henry’s law constant for oxygen at normal
body temperature.
To convert the three-dimensional oxygen concentration in the host brain tissue into its equivalent one-
dimensional concentration, we multiply by the area of a transversal section of the tumour. We assume
that such transversal section is equivalent to the surface area of a sphere of radius r, where A = 4pir2.
Moreover, we consider that r = 200 µm = 2.0× 10−1 mm is the characteristic nutrient diffusion length,
which is consistent with the observed thickness of viable rims of tumour cells in spheroids [42, 93, 94].
Then, A = 4pi(2× 10−1)2 = 16pi × 10−2 mm2 and we obtain that
σ0 = 2.068 nmol mm
−3 · (16pi · 10−2 mm2) ≈ 1.0 nmol mm−1.
- Phenotypic switching parameter (proliferative to migratory) λ1 (in nmol mm
−1). We take
λ1 = σM in the phenotypic switching function f21 = λ1 − σ of glioma cells, where σM is the maximum
oxygen concentration in the host brain tissue. In normal brain tissues, oxygen tension has been estimated
to range from 10 to 80 mmHg [95, 96]. Accordingly, we consider that σM = 2.0 nmol mm
−1, i.e. for an
oxygen pressure equal to 80 mmHg, which is two times higher than the assumed physiological oxygen
concentration σ0.
- Phenotypic switching parameter (migratory to proliferative) λ2 (dimensionless). The effect of
λ2 on glioma invasion is investigated by considering the following overall proliferation rate of glioma cells
B = b
β(σ)
β(σ0)
= b
(λ2 − 1)σ0 + λ1
(λ2 − 1)σ + λ1
σ
σ0
,
where taking into account that λ1 = σM , we can distinguish the following three representative cases:
(i) If 0 < λ2 < 1, then B = b
σM − |λ2 − 1|σ0
σM − |λ2 − 1|σ
σ
σ0
∝ σσM
|λ2 − 1| − σ
.
(ii) If λ2 = 1, then B = b
σ
σ0
∝ σ.
(iii) If λ2 > 1, then B = b
|λ2 − 1|σ0 + σM
|λ2 − 1|σ + σM
σ
σ0
∝ σσM
|λ2 − 1| + σ
.
According to (i)-(iii), we reduce model simulations to the following three parameter values λ2 =
{0.5, 1.0, 2.0}, see Figure S2. Notice that in the limiting case of λ2 = 0 glioma cells do not proliferate,
and therefore we neglect this scenario. Although numerical simulations are obtained for the phenotypic
switching parameter λ2 = 1.0, we report in Section 3 the effect of λ2 variations on glioma invasion, see
Figures S4 and S5.
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λ2 = 2.0
λ2 = 1.0
λ2 = 0.5
λ1 = 2.0
f21(σ) = λ1 - σ 
f12(σ) = λ2 • σ
σ
0 1   2
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1
0
Figure 7: Oxygen-dependant phenotypic switching functions based on the migration/proliferation di-
chotomy of glioma cells.
2.3 Oxygen concentration, σ(x, t)
- Diffusion rate of oxygen Dσ (in mm
2 day−1). Based on experimental data, the oxygen diffusion
rate in tumour tissues at 37 ◦C has been reported equal to 1.75× 10−5 cm2 s−1 [97]. Thus, we consider
that Dσ = 1.51× 102 mm2 day−1, which is in agreement with previous estimates of the oxygen diffusion
rate [22,72,73].
- Oxygen supply rate h1 (in day
−1). Experimental estimates of transvascular permeability to oxygen
PmO2 have been reported in the range 3 × 10−5 to 3 × 10−4 m s−1 [76]. In turn, the ratio of capillary
surface area to volume SV has been observed to vary between 0.13 and 0.33 m
−1 [76]. Then, PmO2 · SV lies
in the range 4.0×10−6 to 1.0×10−4 s−1, which is equivalent to model parameter h1 in the oxygen supply
term of equation (15) [76]. These estimates are also in line with other oxygen supply rates reported [74,75],
i.e. h1 = 3.5× 10−6 and 4.0× 10−6 s−1. Accordingly, we consider that h1 = 3.37× 10−1 day−1, which is
in the range of h1 values above.
- Oxygen consumption rate h2 (in mm cell
−1 day−1). Oxygen consumption rates by tumour cells
have been reported to vary from 2 to 40 µl g−1 min−1 [77, 78]. Considering the average mass of a
cancer cell equal to 10−9 kg [73] and taking into account that 1 µl = 1 mm3, we have that h2 is in
the range 2.88 × 10−3 to 5.76 × 10−2 mm3 cells−1 day−1. As explained above for the estimation of the
physiological oxygen concentration in the host brain tissue σ0, we convert the three-dimensional oxygen
consumption rate into its equivalent one-dimensional rate dividing by the area of a transversal section
of the tumour equal to A = 16pi · 10−2 mm2. Thus, we have that h2 is in the range 5.73 × 10−3 to
1.14× 10−1 mm cell−1 day−1.
2.4 Density of functional tumour vasculature, v(x, t)
- Vasculature dispersal rate Dv (in mm
2 day−1). Experimental estimates of endothelial cell motility
rate in different conditions have been reported between 10−3 and 10−4 mm2 day−1 [98,99]. We consider
that Dv = 5.0× 10−4 mm2 day−1, which is in line with previous models of vascularised tumour growth
[16,22,79].
- Vasculature formation rate g1 (in day
−1). We consider that g1 = 1.0 × 10−1 day−1 by assuming
that blood vessels are formed in a timescale of hours [22, 80,81]. We remark that variations in the value
of g1 change the results only quantitatively, while qualitative phenomena are conserved.
- Oxygen concentration threshold for hypoxia σ∗a (in nmol mm
−1). Although no consensus has been
achieved for hypoxic thresholds, tumour tissues with PO2 levels below 10 mmHg are usually considered
under hypoxia [73,82,83]. Indeed, tissues with oxygen tension between 5.0 and 7.5 mmHg are considered
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under moderate hypoxia, and less than or equal to 2.5 mmHg under severe hypoxia [82]. Accordingly, we
assume that σ∗a = 2.5×10−1 nmol mm−1, see also the derivation of the physiological oxygen concentration
in the host brain tissue σ0 for further details.
- Half-maximal pro-angiogenic factor concentration K (in nmol mm−1). We assume that the
natural decay rate of pro-angiogenic factors is much smaller than the consumption rate by endothelial cells,
i.e. k3  k2 [65]. Then, taking into account the equation of effective pro-angiogenic factor concentration
a =
k1 ρ H˜θ(σ − σ∗a)
k2v + k3
,
the Michaelis-Menten kinetics on the density of functional tumour vasculature in equation (10) is as
follows
a
µ+ a
=
k1ρH˜θ(σ − σ∗a)
k2v + k3
µ+
k1ρH˜θ(σ − σ∗a)
k2v + k3
=
k1
k2
ρ
v
H˜θ(σ − σ∗a)
µ+
k1
k2
ρ
v
H˜θ(σ − σ∗a)
=
ρ
v
H˜θ(σ − σ∗a)
K +
ρ
v
H˜θ(σ − σ∗a)
,
where K = µk2/k1 is a positive constant denoting the concentration of pro-angiogenic factors at which the
functional tumour vasculature formation rate is half-maximal. H˜θ(σ−σ∗a) is a continuous approximation
of the Heaviside decreasing step function H(ξ), defined as H(ξ) = 1 if ξ ≤ 0 and H(ξ) = 0 if ξ > 0, and
given by
H˜θ(σ − σ∗a) = 1−
1
1 + e−2θ(σ−σ∗a)
,
where θ = 1.0 × 101 and K = 1.0 × 101 nmol mm−1. We remark that variations in the value of K
slightly change the results quantitatively, while qualitative phenomena are conserved.
- Vaso-occlusion term G(v, ρ) = g2vρ
n. Figure S3(A) shows a schematic representation of vaso-
occlusion, see also equation (14). We assume that occlusion of tumour blood vessels only occurs for
glioma cell densities greater than N/2, where N is the brain tissue carrying capacity [60]. Accordingly,
we can distinguish the following two representative cases:
(i) If ρ ≤ N/2, then G(v, ρ) = g2vρn = g2 N
n
2n+1
≈ 0.
(ii) If ρ > N/2, then G(v, ρ) = g2vρ
n > g2
Nn
2n+1
> 0.
Considering the functional tumour vasculature at normal density, i.e. v = 1/2, we have that to
satisfy the above assumption on vaso-occlusion induced by glioma cell density low and high values of
g2 and n are required, respectively. Therefore, we take n = 6 and consider the following values of
g2 = {5.0 × 10−13, 5.0 × 10−12, 1.5 × 10−11} cell−n mmn day−1. We remark that lower values of n do
not reproduce the experimental observation that vaso-occlusion starts to occur at tumour cell densities
greater than N/2. Figure S3(B) shows the dependence of the vaso-occlusion term G(v, ρ) in equation (14)
on the density of glioma cells ρ for n = 6, v = 1/2 and values of g2 considered. In turn, Figure S3(C)
provides simulation maps of the vaso-occlusion percentage depending on the diffusion and proliferation
rates of glioma cells at the end of numerical simulations Tf = 3 years. This percentage is obtained as
the ratio between the integral of v(x, Tf ) from x = 0 to the point xv where v = 1/2 and the area of the
rectangle given by xv/2. We observe that vaso-occlusion increases as the proliferation rate of glioma cells
becomes higher, see Figure S3(C).
The term G(v, ρ) = g2vρ
n in equation (14) is selected to model vaso-occlusion because from our
experience extensive tumour blood vessel collapse is taking place when solid stress exceeds a critical
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value [100,101]. Prior to this critical stress threshold, blood vessel collapse is moderate [101]. We remark
that the use of a different expression for G(v, ρ) would change the results only quantitatively and it is
not expected to affect the general conclusions of this study.
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Figure 8: (A) Schematic representation of vaso-occlusion. (B) Dependence of the vaso-occlusion term
G(v, ρ) = g2vρ
n on density of glioma cells ρ for v = 1/2, n = 6 and different values of g2. (C)
Vaso-occlusion percentage, at the end of numerical simulations Tf = 3 years, with respect to intrin-
sic diffusion and proliferation rates of glioma cells for a fixed oxygen consumption rate h2 = 5.73 ×
10−3 mm cell−1 day−1 and g2 = {5.0× 10−14, 5.0× 10−13, 5.0× 10−12, 1.5× 10−11} cells−n mmn day−1
in simulation maps I-IV, respectively. Other model parameters are as in Table 1.
3 Effect of phenotypic switching parameter λ2 on model observables
Numerical simulations are obtained for the phenotypic switching parameter λ2 = 1.0. Thus, in order to
complete the model analysis we investigate the effect of different values of λ2 = {0.5, 1.0, 2.0} on glioma
invasion. Indeed, this set of λ2 values covers the three representative cases discussed above, see also
Figure S2. As shown in Figures S4 and S5, for increasing values of λ2 the tumour front speed increases,
while the infiltration width decreases. We further note that such changes in glioma invasion are similar
with respect to the intrinsic tumour features. Based on these results, we can state that glioma invasion in
response to variations of λ2 is only quantitatively influenced, while qualitative phenomena are conserved.
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Figure 9: Model observables with respect to parameter λ2 for constant functional tumour
vasculature. Simulation maps with respect to the intrinsic proliferation b ∈ [2.73 × 10−4, 2.73 ×
10−2] days−1 and diffusion D ∈ [2.73× 10−3, 2.73× 10−1] mm2 days−1 rates of glioma cells. (A) tumour
front speed and (B) infiltration width for a fixed oxygen consumption h2 = 5.73× 10−3 mm cell−1 day−1
rate, and values of λ2 = {0.5, 1.0, 2.0} in simulation maps I-III, respectively. (A-B) Differences between
simulation maps are provided. The other parameters are as in Table 1.
A Tumor Front Speed
58
39
20
 0
mm/yr
b 
(d
ay
-1
)
b 
(d
ay
-1
)
b 
(d
ay
-1
)
D (mm2/day) D (mm2/day) D (mm2/day)
I   II       III
4.5
3.0
1.5
0.0
mm/yr
D (mm2/day)
b 
(d
ay
-1
)
b 
(d
ay
-1
)
D (mm2/day)
(II - I)                                       (III - II)
λ2 = 0.5 λ2 = 1.0 λ2 = 2.0
                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Min: 0.6667 <> Max: 53.8833
  0
 
 
 58
                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Min: 0.0000 <> Max: 3.0333
  
 
 .
 4.5
B Infiltration Width
63
43
23
 0
mm
b 
(d
ay
-1
)
b 
(d
ay
-1
)
b 
(d
ay
-1
)
D (mm2/day) D (mm2/day) D (mm2/day)
I   II       III
 0.0
-2.3
-5.3
-8.3
mm
D (mm2/day)
b 
(d
ay
-1
)
b 
(d
ay
-1
)
D (mm2/day)
(II - I)                                       (III - II)
λ2 = 0.5 λ2 = 1.0 λ2 = 2.0
                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Min: 5.2750 <> Max: 59.6750
  0
 
 
 63
                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Min: −8.3000 <> Max: 1.0625
  −8.3
 −5.3
 −2.3
 0.0
ur Front Sp ed
Figure 10: Model observables with respect to parameter λ2. Simulation maps with respect to the
intrinsic proliferation b ∈ [2.73× 10−4, 2.73× 10−2] days−1 and diffusion D ∈ [2.73× 10−3, 2.73× 10−1]
mm2 days−1 rates of glioma cells. (A) tumour front speed and (B) infiltration width for fixed oxygen
consumption h2 = 5.73× 10−3 mm cell−1 day−1 and vaso-occlusion g2 = 5.0× 10−12 cells−n mmn day−1
rates, and values of model parameter λ2 = {0.5, 1.0, 2.0} in simulation maps I-III, respectively. (A-B)
Differences between simulation maps are provided. The other parameters are as in Table 1.
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